• Spruce Biosciences flagged new natural history findings from its Study 250-902 in severe pediatric Sanfilippo syndrome type B (MPS IIIB).
• Results have not yet been presented; disclosure is scheduled for the Child Neurology Society annual meeting on Oct. 15, 2026.
• Analyses map how cognition, motor function, communication, and adaptive skills typically worsen over time in the studied population.
• Data aim to sharpen disease-progression benchmarks that can guide clinical development strategy in MPS IIIB.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610081605BIZWIRE_USPR_____20261008_BW501925) on October 08, 2026, and is solely responsible for the information contained therein.